1. Unicycive Therapeutics faces a class action securities lawsuit. 2. Claims involve false statements regarding FDA compliance and drug application. 3. Investors can join the lawsuit until October 14, 2025. 4. No costs for class members to participate in the lawsuit. 5. Levi & Korsinsky has a strong track record in securities litigation.
The lawsuit indicates potential serious reputational damage and financial liability for UNCY. Companies facing such actions often see immediate declines in stock value, as seen in cases like Theranos.
Given the serious allegations of fraud, the lawsuit is likely to impact investor sentiment and stock performance significantly.
Lawsuit announcements typically create immediate market reactions, evident in past securities cases. Thus, UNCY could experience short-term price pressure as investors react quickly.
NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. ("Unicycive Therapeutics, Inc." or the "Company") (NASDAQ:UNCY) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Unicycive Therapeutics, Inc. investors who were adversely affected by alleged securities fraud between March 29, 2024 and June 27, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?prid=165266&wire=4
UNCY investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) Unicycive's readiness and ability to satisfy the FDA's manufacturing compliance requirements was overstated; (ii) the oxylanthanum carbonate new drug application's regulatory prospects were likewise overstated; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Unicycive Therapeutics, Inc. during the relevant time frame, you have until October 14, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-october-14-2025-in-unicycive-therapeutics-inc-lawsuit--uncy-302547265.html
SOURCE Levi & Korsinsky, LLP